Related Experiment Video
Updated: Feb 24, 2026

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
Metabolic Perturbation Exacerbates Sinoatrial Node Dysfunction in Heart Failure
Insights
Ceramides disrupt heart failure sinoatrial node function by altering mitochondrial metabolism, shifting from fat oxidation to carbohydrate use. This metabolic shift impairs heart rhythm, suggesting ceramides as a therapeutic target for sinoatrial node dysfunction in heart failure.
Area of Science:
- Cardiology
- Mitochondrial Biology
- Metabolic Research
Background:
- Heart failure (HF) affects millions, with high mortality. Sinoatrial node dysfunction (SAND) is a complication increasing HF morbidity and mortality.
- Mitochondrial dysfunction is implicated in HF, but its specific role in SAND remains unclear.
- Understanding SAND mechanisms can reveal therapeutic targets to improve HF patient outcomes.
Purpose of the Study:
- To investigate the metabolic alterations in the sinoatrial node (SAN) during heart failure (HF).
- To determine the role of ceramides in mitochondrial dysfunction and impaired automaticity in HF-related SAND.
- To explore ceramides as potential therapeutic targets for SAND in HF.
Main Methods:
- Multi-omics approach, ultra-resolution imaging, and functional analyses were used to study SAN metabolism in HF.
- Metabolomics identified increased glucosylceramides and ceramides in HF SAN mitochondria.
- Functional assays tested the impact of ceramides on mitochondrial metabolism and SAN automaticity.
Main Results:
- HF SAN mitochondria showed reduced fatty acid oxidation and increased reliance on carbohydrate catabolism and ketone bodies.
- Elevated ceramide levels were identified as a key factor in mitochondrial dysfunction.
- Ceramides induced a dose-dependent shift from oxidative phosphorylation to glycolysis, impairing SAN automaticity.
Conclusions:
- Ceramides are active mediators of mitochondrial and metabolic dysfunction in the heart failure sinoatrial node.
- Metabolic derangements, particularly involving ceramides, contribute significantly to sinoatrial node dysfunction in HF.
- Targeting ceramides may offer a novel therapeutic strategy for mitigating sinoatrial node dysfunction in heart failure patients.
Abstract:
Heart failure (HF) affects approximately 6.2 million people in the United States, with a 5-year mortality exceeding 50%. Bradyarrhythmia, a known complication in HF due to sinoatrial node (SAN) dysfunction (SAND), increases the morbidity and mortality of HF patients. Insights into the mechanistic underpinnings of SAND in HF could therefore uncover vital therapeutic targets to improve clinical outcomes. The SAN cells are endowed with a dense mitochondrial network crucial for sustaining their pacemaking function on a beat-to-beat basis. We have previously demonstrated significant disruptions in the mitochondrial-sarcoplasmic reticulum connectomics, resulting in abnormal mitochondrial Ca 2+ handling and impaired mitochondrial function in HF. Here, we hypothesize that the metabolic perturbation is one of the critical mechanisms underlying SAND. To this end, we took advantage of a multi-omics approach combined with ultra-resolution imaging and functional analyses to decipher the metabolic shift that transpires in the HF SAN. Our findings revealed significant metabolic remodeling within the SAN mitochondria in HF, with a diminished reliance on fatty acid β-oxidation, enhanced utilization of ketone bodies, and heightened dependence on carbohydrate catabolism. Notably, metabolomics analyses identified the pronounced increase of glucosylceramides and ceramides as one of the mechanisms leading to mitochondrial dysfunction. We directly test this hypothesis and demonstrate that ceramides induce a dose-dependent metabolic shift from oxidative phosphorylation to glycolysis. Importantly, these alterations lead to a significant impairment in SAN automaticity in a dose-dependent manner. Collectively, the findings support the notion that ceramides are not only markers of metabolic derangement, but also active mediators of mitochondrial and metabolic dysfunction in the SAN. Overall, the study provides evidence that ceramides may be a potential therapeutic target for mitigating SAND in HF.
More Related Videos
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
09:32Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice
Published on: October 23, 2016
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitral Regurgitation I: Introduction
Heart Failure Drugs: Diuretics
Mitral Stenosis I: Introduction